NCT07047690尚未招募2 期
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Galderma R&D
- 入组人数
- 162
- 主要终点
- Change From Baseline (BL) in Modified Rodnan Skin Score (mRSS) at Week 52
研究概览
简要总结
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 years of age or older, at the time of signing the Informed Consent Form.
- •Classification of systemic sclerosis (SSc) as defined by the 2013 American College of Rheumatology [ACR]/European League Against Rheumatism [EULAR] criteria.
- •Modified Rodnan Skin Score.
- •Diffuse cutaneous systemic sclerosis (DcSSc) participants and modified Rodnan Skin Score (mRSS) of greater than equal to (>=)12 and less than (<)30 at both screening and baseline
- •Limited cutaneous systemic sclerosis (LcSSc) participants with mRSS >=8 at both screening and baseline. LcSSc participants with positive anti-centromere at screening are excluded.
- •Disease duration in DcSSc participants <= 5 years from screening and LcSSc participants <=2 years from screening is defined as the time from the first non-Raynaud's phenomenon manifestation of SSc.
- •Participants are permitted to receive the following background therapies stable for at least 3 months prior to baseline, including any combination of the following:
- •Nintedanib (<150mg twice daily) and/or
- •One of the following:
- •Methotrexate (MTX) (<25mg weekly) or
- •Mycophenolate mofetil (MMF), mycophenolate sodium (MPS), or mycophenolic acid (MPA) (<3000mg daily MMF, <2160mg daily for MPS or MPA) NOTE: MTX should not be used in combination with MMF/MPS/MPA
- •Participants with evidence for active or progressive disease.
- •Men (whose female partner can become pregnant) and women of childbearing potential will be required to use effective means of contraception or commit to true abstinence, when this is in line with preferred and usual lifestyle of the participant, during the study and for at least 12 weeks after receiving the last study treatment.
- •Female participants of non-childbearing potential
- •Signed informed consent
排除标准
- •Anti-centromere antibody positive at screening for participants with LcSSc.
- •Anti-RNA polymerase 3 antibody positive for participants with a disease duration >18months.
- •Creatinine clearance <30 milli liter per minute [ml/min] (calculated by Cockcroft-Gault formula).
- •Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HbcAb], hepatitis C [HCV] antibody with positive confirmatory test for hepatitis C virus [HCV] antibody with positive HCV RNA, or human immunodeficiency virus [HIV] antibody).
- •FVC <50% of predicted normal value, and DLCO <40% of predicted normal value (corrected for Hb) at screening and baseline.
- •Known diagnosis of clinically significant respiratory disorders other than ILD, including severe chronic obstructive pulmonary disease, severe asthma, recent (within 3 months) severe respiratory infections or history of recurrent respiratory infections, smoking, and any other respiratory condition that, in the opinion of the investigator, could interfere with the study or pose a risk to the participant.
- •Currently listed and/or anticipated to be listed for lung transplantation within the next 12 months.
- •Cardiovascular disease with clinically significant arrhythmia requiring therapy, congestive heart failure (New York Heart Association Class III-IV functional capacity), unstable angina, uncontrolled hypertension, Cor pulmonale, or symptomatic pericardial effusion.
- •History of myocardial infarction in the last 6 months prior to screening.
- •Pulmonary hypertension WHO Functional Class III or higher (as defined by WHO 2009) requiring treatment.
- •Clinical signs of severe malabsorption in the opinion of the investigator or needing parenteral nutrition.
- •History of scleroderma renal crisis (SRC) 6 months prior to screening.
- •Participants with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment).
- •Body weight of <30.0 kilogram (Kg) at screening or BL
- •Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed, or unwilling to use appropriate contraception measures during the study period
- •Previous treatment with nemolizumab
- •Participants with the primary diagnosis of a rheumatic autoimmune disease other than SSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, systemic vasculitis, Sjogren's syndrome, anti-synthetase syndrome, or mixed CTD, as determined by the investigator with consultation of the medical monitors
- •Systemic sclerosis-like illness including but not limited to localized scleroderma (morphea), eosinophilic fasciitis, sclerodermoid graft-versus-host disease, fibro mucinous conditions (scleredema, scleromyxedema), scleroderma-like conditions that are associated with environmental chemical and drug exposure (e.g., toxic rapeseed oil, vinyl chloride, bleomycin, gadolinium-based contrast agents [nephrogenic systemic fibrosis], or due to metabolic disease)
- •History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study treatment excipient
- •Known active bacterial, viral, fungal, or any major episode of infection requiring hospitalization or treatment with IV antibiotics or antivirals within 4 weeks prior to screening, or oral antibiotics within 2 weeks prior to screening. Participants may be rescreened once the infection has resolved.
- •History of a primary immunodeficiency
- •History of Bone Morrow Transplantation. Chimeric Antigen Receptor (CAR)-T Cell Therapy or any other genetically engineering cells
- •History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for (1) basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the BL visit, or (2) actinic keratoses that have been treated
- •History of alcohol or substance abuse dependence or any condition that, in the investigator's opinion makes the participant unreliable to following instructions and complete the study
- •In the opinion of the investigator, the participant has any medical condition, including clinically significant pulmonary abnormalities, or psychological condition,or clinically significant laboratory abnormalities that could pose undue risk to the participant, prevent study completion or adversely affect the validity or interpretability of the study measurements or interfere with the study assessments, or impede the participant's ability to complete the study.
- •Participant has not adhered to the restrictions in select treatments prior to screening or is not expected to be compliant with restrictions during the study
研究组 & 干预措施
Nemolizumab Dose 1
Experimental
干预措施: Nemolizumab (Drug)
Nemolizumab Dose 2
Experimental
干预措施: Nemolizumab (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline (BL) in Modified Rodnan Skin Score (mRSS) at Week 52
时间窗: Baseline, at Week 52
mRSS is the assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering).Cutaneous thickness is assessed in 17 body surface areas using a 0-3 scale, where mRSS of score 0="normal" with fine wrinkles but no skin thickness; score 1="mild" skin thickness; score 2= "moderate" skin thickness with difficulty in making skin folds and no wrinkles; and score 3="severe" skin thickness with inability to make skin folds between 2 examining fingers. Where higher score indicating more severe disease.
次要结局
- Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52(Baseline, at Week 52)
- Percent Change From Baseline in Clinician's Global Assessment (CGA) Score at Week 52(Baseline, at Week 52)
- Incidence and Severity of TEAEs, Treatment-Emergent SAEs, Treatment-Emergent AEs of Special Interest (AESIs), Significant SSc-Related TEAEs, TEAEs Leading to Investigational Product Discontinuation and Study Discontinuation.(From baseline of study intervention to 12 weeks after last dose (52 weeks))
- Incidence of Abnormal Vital Signs(From baseline of study intervention to 12 weeks after last dose (52 weeks))
- Percent change from Baseline in mRSS at Week 52(Baseline, at Week 52)
- Incidence of Abnormal Electrocardiogram (ECG) Findings(From baseline of study intervention to 12 weeks after last dose (52 weeks))
- Incidence of Abnormal Weight Change(From baseline of study intervention to 12 weeks after last dose (52 weeks))
- Change From Baseline in Forced Vital Capacity (FVC) at Week 52(Baseline, at Week 52)
- Change From Baseline in mRSS at Weeks 8, 12, 24, 28, 36, 44, 52(Baseline, at Week 8, 12, 24, 28, 36, 44, 52)
- Change from Baseline in Percent Predicted FVC (ppFVC) at Week 52(Baseline, at Week 52)
- Percent Change From Baseline in Patient's Global Assessment (PGA) Score at Week 52(Baseline, at Week 52)
- Proportion of Responders to the Treatment Based on the Revised Composite Response Index in Systemic Sclerosis (rCRISS) at Week 52(At Week 52)
- Incidence of Abnormal Laboratory Parameters(From baseline of study intervention to 12 weeks after last dose (52 weeks))
研究者
相似试验
终止
1 期
Hypertrophic Scar Prevention by Novel Topical Gel ApplicationHypertrophic ScarNCT03403621Mayo Clinic6
已完成
2 期
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisArthritis, PsoriaticNCT02719171AbbVie185
已完成
3 期
Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-ConstipationConstipationNCT00936884Bausch Health Americas, Inc.50
进行中（未招募）
3 期
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical RemissionGiant Cell ArteritisNCT05380453Novartis Pharmaceuticals151
已完成
3 期
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2NCT01733758GlaxoSmithKline494